{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:15:40Z","timestamp":1788308140318,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hormozgan University of Medical Sciences, , Iran, Islamic Republic Of","award":["4030358"],"award-info":[{"award-number":["4030358"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a chronic inflammatory skin disease that can substantially impair health-related quality of life (HRQoL). While biologic therapies are widely used in patients with psoriasis, their real-world impact on HRQoL within biologic-eligible patient populations remains insufficiently explored, particularly in resource-constrained settings. This cross-sectional study assessed HRQoL in adult patients with psoriasis in Iran who were considered clinically eligible for biologic therapy according to Iranian treatment guideline criteria. HRQoL was assessed via the EQ-5D-5\u00a0L, EQ-VAS, and Dermatology Life Quality Index (DLQI). Multiple linear and logistic regression analyses were conducted to identify sociodemographic and clinical factors associated with HRQoL. The mean scores were 0.51 (EQ-5D-5\u00a0L), 59.7 (EQ-VAS), and 11.9 (DLQI). A lower HRQoL was significantly associated with greater disease severity, infliximab use, less than six years of education, lack of supplementary insurance, disease duration\u2009\u2264\u20095 years, and being married. Multivariate analysis confirmed the independent effects of these variables. The most commonly reported issues were pain\/discomfort (78.5%) and anxiety\/depression (75.9%). Patients with psoriasis eligible for biologic therapy in southern Iran experienced poor HRQoL. These real-world findings highlight the need for patient-centered approaches and policy reforms that enhance insurance coverage, improve health literacy, and ensure equitable access to psoriasis care in resource-constrained settings.<\/jats:p>","DOI":"10.1038\/s41598-026-55839-5","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:04:56Z","timestamp":1781161496000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life in patients with psoriasis eligible for biologic therapy in southern Iran via the EQ-5D-5\u00a0L and DLQI"],"prefix":"10.1038","volume":"16","author":[{"given":"Ali","family":"Mouseli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shirvani Shiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Tatari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Raei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimetcan Mehmet","family":"Orhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Noroozian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmeh","family":"Bordbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadegh","family":"Alishavandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sadegh","family":"Javidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Zahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"55839_CR1","unstructured":"WHO. Global report on psoriasis. (2016)."},{"key":"55839_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1186\/s12889-019-7775-0","volume":"19","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. The psychosocial adaptation of patients with skin disease: a scoping review. BMC Public. Health. 19, 1404. https:\/\/doi.org\/10.1186\/s12889-019-7775-0 (2019).","journal-title":"BMC Public. Health"},{"key":"55839_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13690-024-01332-2","volume":"82","author":"R Ravangard","year":"2024","unstructured":"Ravangard, R., Mirzaei, M., Ghahartars, M. & Jafari, A. Economic burden of psoriasis in Southern Iran in 2022. Archives Public. Health. 82, 104 (2024).","journal-title":"Archives Public. Health"},{"key":"55839_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/biomedicines9111511","volume":"9","author":"A Campanati","year":"2021","unstructured":"Campanati, A. et al. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines 9, 1511 (2021).","journal-title":"Biomedicines"},{"key":"55839_CR5","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/life12122050","volume":"12","author":"AC Nicolescu","year":"2022","unstructured":"Nicolescu, A. C. et al. Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life 12, 2050 (2022).","journal-title":"Life"},{"key":"55839_CR6","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1186\/s12889-023-16758-6","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. -q. Factors associated with quality of life in Chinese people with psoriasis: a cross-sectional study. BMC Public. Health. 23, 1860. https:\/\/doi.org\/10.1186\/s12889-023-16758-6 (2023).","journal-title":"BMC Public. Health"},{"key":"55839_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/14737167.2014.914437","volume":"14","author":"M Augustin","year":"2014","unstructured":"Augustin, M. & Radtke, M. A. Quality of life in psoriasis patients. Expert Rev. PharmacoEcon. Outcomes Res. 14, 559\u2013568. https:\/\/doi.org\/10.1586\/14737167.2014.914437 (2014).","journal-title":"Expert Rev. PharmacoEcon. Outcomes Res."},{"key":"55839_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.22034\/ijd.2020.244330.1195","volume":"25","author":"Y Nahidi","year":"2022","unstructured":"Nahidi, Y., Kiafar, B., Sadeghinejad, Z., Jarahi, L. & Mallakifard, T. Quality of life of psoriasis patients and their partners in Mashhad, Iran. Iran. J. Dermatology. 25, 17\u201323. https:\/\/doi.org\/10.22034\/ijd.2020.244330.1195 (2022).","journal-title":"Iran. J. Dermatology"},{"key":"55839_CR9","doi-asserted-by":"publisher","first-page":"1183685","DOI":"10.3389\/fmed.2023.1183685","volume":"10","author":"EA Belachew","year":"2023","unstructured":"Belachew, E. A., Chanie, G. S., Gizachew, E. & Sendekie, A. K. Health-related quality of life and its determinants among patients with psoriasis at a referral hospital in Northwest Ethiopia. Front. Med. 10, 1183685. https:\/\/doi.org\/10.3389\/fmed.2023.1183685 (2023).","journal-title":"Front. Med."},{"key":"55839_CR10","first-page":"0","volume":"18","author":"M Moradi","year":"2015","unstructured":"Moradi, M. et al. Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey. Arch. Iran. Med. 18, 0\u20130 (2015).","journal-title":"Arch. Iran. Med."},{"key":"55839_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102914","author":"S Osanto","year":"2024","unstructured":"Osanto, S. et al. Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: A systematic review. eClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2024.102914 (2024).","journal-title":"eClinicalMedicine"},{"key":"55839_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJM199603283341306","volume":"334","author":"MA Testa","year":"1996","unstructured":"Testa, M. A. & Simonson, D. C. Assessment of quality-of-life outcomes. N. Engl. J. Med. 334, 835\u2013840. https:\/\/doi.org\/10.1056\/NEJM199603283341306 (1996).","journal-title":"N. Engl. J. Med."},{"key":"55839_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/09546630601121060","volume":"18","author":"R Shikiar","year":"2007","unstructured":"Shikiar, R. et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient\u2010reported outcomes from a Phase II randomized controlled trial. J. Dermatolog. Treat. 18, 25\u201331. https:\/\/doi.org\/10.1080\/09546630601121060 (2007).","journal-title":"J. Dermatolog. Treat."},{"key":"55839_CR14","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ad.2011.03.022","volume":"102","author":"F Valenzuela","year":"2011","unstructured":"Valenzuela, F., Silva, P., Valdes, M. P. & Papp, K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr. 102, 810\u2013816. https:\/\/doi.org\/10.1016\/j.ad.2011.03.022 (2011).","journal-title":"Actas Dermosifiliogr."},{"key":"55839_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman, M. et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5 L). Qual. Life Res. 20, 1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x (2011).","journal-title":"Qual. Life Res."},{"key":"55839_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin, R. & Charro, F. EQ-SD: a measure of health status from the EuroQol Group. Ann. Med. 33, 337\u2013343. https:\/\/doi.org\/10.3109\/07853890109002087 (2001).","journal-title":"Ann. Med."},{"key":"55839_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY FINLAY","year":"1994","unstructured":"FINLAY, A. Y. & KHAN, G. K. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x (1994).","journal-title":"Clin. Exp. Dermatol."},{"key":"55839_CR18","doi-asserted-by":"crossref","unstructured":"De Korte, J., Mombers, F. M., Bos, J. D. & Sprangers, M. A. Quality of life in patients with psoriasis: a systematic literature review. In Proceedings of the Journal of Investigative Dermatology Symposium Proceedings. 140\u2013147. (2004).","DOI":"10.1046\/j.1087-0024.2003.09110.x"},{"key":"55839_CR19","first-page":"123","volume":"14","author":"M Ghajarzadeh","year":"2011","unstructured":"Ghajarzadeh, M., Kheirkhah, S., Ghiasi, M. & Hoseini, N. Depression and quality of life in psoriasis and psoriatic arthritis patients. Iran. J. Dermatology. 14, 123\u2013128 (2011).","journal-title":"Iran. J. Dermatology"},{"key":"55839_CR20","first-page":"166","volume":"2","author":"S Zandi","year":"2011","unstructured":"Zandi, S., Shamsi Meymandi, S., Hasheminasab Gorji, S. & Sabouri Shahrebabak, F. Evaluation of quality of life in patients with psoriasis. J. Dermatology Cosmet. 2, 166\u2013173 (2011).","journal-title":"J. Dermatology Cosmet."},{"key":"55839_CR21","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin, R. et al. Switches between biologics in patients with moderate-to-severe psoriasis: Results from the French cohort PSOBIOTEQ. J. Eur. Acad. Dermatol. Venereol. 36, 2101\u20132112. https:\/\/doi.org\/10.1111\/jdv.18409 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"55839_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.61384\/r.c.a..v5i1.844","volume":"5","author":"DGO Paredes","year":"2025","unstructured":"Paredes, D. G. O. & Charleston, M. C. Efficacy and Safety of Biologic Therapies in the Treatment of Moderate-to-Severe Plaque Psoriasis. Estudios y Perspectivas Revista Cient\u00edfica y Acad\u00e9mica. 5, 356\u2013366 (2025).","journal-title":"Estudios y Perspectivas Revista Cient\u00edfica y Acad\u00e9mica"},{"key":"55839_CR23","unstructured":"Population and Housing Censuses.\u00a0https:\/\/old.sci.org.ir\/Portals\/1\/census\/2016\/Census_2016_Selected_Findings.pdf."},{"key":"55839_CR24","unstructured":"MapChart. Asia - Detailed map. https:\/\/www.mapchart.net\/asia-detailed.html#."},{"key":"55839_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370, 1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X (2007).","journal-title":"Lancet"},{"key":"55839_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.30699\/jambs.26.119.1","volume":"26","author":"F Pezeshkpoor","year":"2018","unstructured":"Pezeshkpoor, F., Zabolinejad, N., Golnouri, F., Torabi, S. & Abed, J. Quality of life in psoriasis patients and its correlation with disease severity. J. Adv. Med. Biomed. Res. 26, 1\u20135. https:\/\/doi.org\/10.30699\/jambs.26.119.1 (2018).","journal-title":"J. Adv. Med. Biomed. Res."},{"key":"55839_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1523-1747.ep12329912","volume":"106","author":"SR Feldman","year":"1996","unstructured":"Feldman, S. R. et al. The Self-Administered Psoriasis Area and Severity Index is valid and reliable. J. Invest. Dermatol. 106, 183\u2013186. https:\/\/doi.org\/10.1111\/1523-1747.ep12329912 (1996).","journal-title":"J. Invest. Dermatol."},{"key":"55839_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1052155","author":"N Moradi","year":"2022","unstructured":"Moradi, N., Poder, T. G., Safari, H., Mojahedian, M. M. & Ameri, H. Psychometric properties of the EQ-5D-5 L compared with EQ-5D-3 L in cancer patients in Iran. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.1052155 (2022).","journal-title":"Front. Oncol."},{"key":"55839_CR29","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s11136-023-03378-1","volume":"32","author":"S Afshari","year":"2023","unstructured":"Afshari, S. et al. A national survey of Iranian general population to estimate a value set for the EQ-5D-5 L. Qual. Life Res. 32, 2079\u20132087. https:\/\/doi.org\/10.1007\/s11136-023-03378-1 (2023).","journal-title":"Qual. Life Res."},{"key":"55839_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol","year":"1990","unstructured":"EuroQol -. a new facility for the measurement of health-related quality of life. Health Policy. 16, 199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9 (1990).","journal-title":"Health Policy"},{"key":"55839_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-5945-4-8","volume":"4","author":"S Aghaei","year":"2004","unstructured":"Aghaei, S., Sodaifi, M., Jafari, P., Mazharinia, N. & Finlay, A. Y. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol. 4, 8. https:\/\/doi.org\/10.1186\/1471-5945-4-8 (2004).","journal-title":"BMC Dermatol."},{"key":"55839_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo, Y., Thomas, C. L., Harrison, M. A., Sam Salek, M. & Finlay, A. Y. Translating the Science of Quality of Life into Practice: What Do Dermatology Life Quality Index Scores Mean? J. Invest. Dermatology. 125, 659\u2013664. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23621.x (2005).","journal-title":"J. Invest. Dermatology"},{"key":"55839_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra, M. K. A., Salek, M. S., Camilleri, L., Sturkey, R. & Finlay, A. Y. Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data. Dermatology 230, 27\u201333. https:\/\/doi.org\/10.1159\/000365390 (2015).","journal-title":"Dermatology"},{"key":"55839_CR34","first-page":"4","volume":"2017","author":"S Kobra","year":"2017","unstructured":"Kobra, S. & Tahereh, N. G. Relationship between quality of life and disease severity in patients with psoriasis. Nursing Pract. Today 2017, 4 (2017).","journal-title":"Nursing Pract. Today"},{"key":"55839_CR35","first-page":"113","volume":"19","author":"A Robabeh","year":"2016","unstructured":"Robabeh, A. et al. Quality of life in patients with psoriasis: A cross-sectional study in a dermatology referral hospital in Tehran, Iran. Iran. J. Dermatology. 19, 113\u2013118 (2016).","journal-title":"Iran. J. Dermatology"},{"key":"55839_CR36","unstructured":"Calculator.net. Random Number Generator.\u00a0https:\/\/www.calculator.net\/random-number-generator.html."},{"key":"55839_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"J Schmitt","year":"2005","unstructured":"Schmitt, J. & Wozel, G. The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis. Dermatology 210, 194\u2013199. https:\/\/doi.org\/10.1159\/000083509 (2005).","journal-title":"Dermatology"},{"key":"55839_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","volume":"51","author":"CF Rosen","year":"2011","unstructured":"Rosen, C. F. et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 51, 571\u2013576. https:\/\/doi.org\/10.1093\/rheumatology\/ker365 (2011).","journal-title":"Rheumatology"},{"key":"55839_CR39","doi-asserted-by":"publisher","first-page":"2231847","DOI":"10.1080\/07853890.2023.2231847","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study. Ann. Med. 55, 2231847. https:\/\/doi.org\/10.1080\/07853890.2023.2231847 (2023).","journal-title":"Ann. Med."},{"key":"55839_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2174\/1574886317666220526153518","volume":"18","author":"H Karami","year":"2023","unstructured":"Karami, H. et al. Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study. Curr. Drug Saf. 18, 484\u2013495. https:\/\/doi.org\/10.2174\/1574886317666220526153518 (2023).","journal-title":"Curr. Drug Saf."},{"key":"55839_CR41","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s11136-021-02792-7","volume":"30","author":"H Karami","year":"2021","unstructured":"Karami, H., Shirvani Shiri, M., Rezapour, A., Sarvari Mehrabadi, R. & Afshari, S. The association between diabetic complications and health-related quality of life in patients with type 2 diabetes: a cross-sectional study from Iran. Qual. Life Res. 30, 1963\u20131974. https:\/\/doi.org\/10.1007\/s11136-021-02792-7 (2021).","journal-title":"Qual. Life Res."},{"key":"55839_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1091330","author":"H Karami","year":"2023","unstructured":"Karami, H. et al. Factors associated with health-related quality of life in patients with Crohn\u2019s disease in Iran: A prospective observational study. Front. Med. https:\/\/doi.org\/10.3389\/fmed.2022.1091330 (2023).","journal-title":"Front. Med."},{"key":"55839_CR43","first-page":"1146","volume":"5","author":"A Darjani","year":"2014","unstructured":"Darjani, A. et al. Quality of life in psoriatic patients: a study using the short form-36. Int. J. Prev. Med. 5, 1146 (2014).","journal-title":"Int. J. Prev. Med."},{"key":"55839_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1684\/ejd.2014.2511","volume":"25","author":"H \u00c7akmur","year":"2015","unstructured":"\u00c7akmur, H. & Dervi\u015f, E. The relationship between quality of life and the severity of psoriasis in Turkey. Eur. J. Dermatology. 25, 169\u2013176 (2015).","journal-title":"Eur. J. Dermatology"},{"key":"55839_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1046\/j.1365-2133.1997.19472062.x","volume":"137","author":"DG FORTUNE","year":"1997","unstructured":"FORTUNE, D. G., MAIN, C. J., O\u2019SULLIVAN, T. M. & GRIFFITHS, C. E. M. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br. J. Dermatol. 137, 755\u2013760. https:\/\/doi.org\/10.1046\/j.1365-2133.1997.19472062.x (1997).","journal-title":"Br. J. Dermatol."},{"key":"55839_CR46","first-page":"15","volume":"5","author":"B Nabaei","year":"2002","unstructured":"Nabaei, B., Safizadeh, H. & Hallaji, Z. Evaluation of quality of life in psoriatic patients and comparison with healthy control. Iran. J. Dermatol. 5, 15\u201321 (2002).","journal-title":"Iran. J. Dermatol."},{"key":"55839_CR47","first-page":"309","volume":"10","author":"J Zari","year":"2007","unstructured":"Zari, J., Naser, T. M., Ahmad Reza, T. & Yalda, N. Evaluation of the psoriasis disability index in psoriatic patients. Iran. J. Dermatology. 10, 309\u2013315 (2007).","journal-title":"Iran. J. Dermatology"},{"key":"55839_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22034\/ijd.2020.108062","volume":"23","author":"H Eftekhari","year":"2020","unstructured":"Eftekhari, H., Azimi, S. Z., Darjani, A., Rafiei, R. & Amookhteh, M. The quality of life and its related factors in patients with psoriasis. Iran. J. Dermatology. 23, 9\u201315. https:\/\/doi.org\/10.22034\/ijd.2020.108062 (2020).","journal-title":"Iran. J. Dermatology"},{"key":"55839_CR49","first-page":"479","volume":"6","author":"R Bidaki","year":"2023","unstructured":"Bidaki, R. et al. The rate of social acceptance in psoriasis patients: A cross-sectional study in Iran. J. Iran. Med. Counc. 6, 479\u2013487 (2023).","journal-title":"J. Iran. Med. Counc."},{"key":"55839_CR50","first-page":"143","volume":"4","author":"K Soltandehghan","year":"2017","unstructured":"Soltandehghan, K. & Najafi-Ghezeljeh, T. Relationship between quality of life and disease severity in patients with psoriasis. Nurs. Pract. Today. 4, 143\u2013153 (2017).","journal-title":"Nurs. Pract. Today."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55839-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:45:56Z","timestamp":1788306356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55839-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55839"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55839-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent prior to participation.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. This study received ethical approval from the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1403.322) in 2024.","order":3,"name":"Ethics","label":"Institutional review board","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27495"}}